Added to YB: 2026-05-12
Pitch date: 2026-05-10
XENE [neutral]
Xenon Pharmaceuticals Inc.
-0.38%
current return
Author Info
No bio for this author
Company Info
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders.
Market Cap
$5.5B
Pitch Price
$55.99
Price Target
N/A
Dividend
N/A
EV/EBITDA
-10.11
P/E
-11.99
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Q1 Earnings Wire May 8, 2026 PM Drop - Xenon Pharmaceuticals Inc.
XENE (earnings): Q1 net loss $102.3M on R&D ramp. $1.34B cash post-$700M raise extends runway to 2029. X-TOLE2 hit: -42.7% MPC at 25mg (p<0.0001); NDA filing Q3'26. 5 Phase 3s enrolling (epilepsy/MDD); X-NOVA2 MDD data H1'27. NaV1.7 & KV7 pain Phase 1s done H2'26. Stock flat on CEO insider sale overhang despite strong fundamentals.
Read full article (1 min)